Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy »

Stanford Health Care

Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-I trial) AMERICAN JOURNAL OF CARDIOLOGY Kandzari, D. E., Granger, C. B., Simoons, M. L., White, H. D., Simes, J., Mahaffey, K. W., Gore, J., Weaver, W. D., Longstreth, W. T., Stebbins, A., Lee, K. L., Califf, R. M., Topol, E. J. 2004; 93 (4): 458-461

Abstract

Of 592 patients in the Global Utilization of Streptokinase and tPA for Occluded Arteries-I trial who had a stroke during initial hospitalization, the risk for intracranial hemorrhage was significantly greater in those with recent facial or head trauma (odds ratio 13.0, 95% confidence interval 3.4 to 85.5); dementia was additionally associated with an increased risk for intracranial hemorrhage (odds ratio 3.4, 95% confidence interval 1.2 to 10.2). Because facial or head trauma may greatly influence treatment decisions, this risk factor should be incorporated into models designed to estimate the risks and benefits of fibrinolytic therapy.

View details for DOI 10.1016/j.amjcard.2003.10.043

View details for Web of Science ID 000188968800016

View details for PubMedID 14969623